Previous 10 | Next 10 |
Summary Zanidatamab passed the key test in December that led to partner Jazz's opt-in. HERIZON-BTC-01 results exceeded expectations with a much longer duration of response. Zanidatamab is now Jazz's responsibility and Zymeworks stands to benefit as the program moves forward. Wit...
Summary Pharmaceuticals and biotechnology still look attractive. Healthcare providers are close to their baseline in both valuation and quality. I look at iShares Genomics Immunology and Healthcare ETF, an ETF in genomics and immunology. 10 stocks cheaper than their peers in Nov...
Summary Today, we take a deeper look at mid-cap oncology name Mirati Therapeutics for the first time in several years. The company's first FDA approval and some other positive milestones have been overshadowed over the past two months by some disappointing trial data. This has cause...
BeiGene ( NASDAQ: BGNE ) said that the Government of Quebec will publicly fund tyrosine kinase, Brukinsa, to treat adult patients with Waldenström's macroglobulinemia (WM), a rare blood cancer. BeiGene Canada said it was working with other provinces for the addition of this ...
Quebec becomes first province to cover PrBRUKINSA® (zanubrutinib) for the Treatment of Waldenström's macroglobulinemia Canada NewsWire First and only BTK inhibitor to be granted provincial formulary approval TORONTO , Feb. 6, 2023 /CNW/ - Be...
BeiGene Releases Report and Launches CancerandMentalHealth.com in Conjunction with World Cancer Day to Help Patients and Caregivers Overcome Barriers to Access BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, has released a report highlighting the challe...
Summary Baillie Gifford’s 13F portfolio value decreased from ~$96.99B to ~$95.96B this quarter. They increased NVIDIA, Shopify, NIO Inc., SEA Ltd., Roblox, DoorDash, and Ginkgo Bioworks while reducing Illumina, Ferrari N.V., Arthur J. Gallagher & Co., Albemarle, Meta Platform...
Summary According to the financial report of Johnson & Johnson, a partner of AbbVie, sales of Imbruvica decreased in the 4th quarter of 2022 due to increased competition. In less than six months, Humira's biosimilars will go on sale in the United States. Botox Cosmetic sales wer...
Summary BeiGene's BRUKINSA has recently obtained approval from the FDA for the treatment of small lymphocytic lymphoma and chronic lymphocytic leukemia. BGNE's current valuations are still appealing based on a review of the company's growth and profitability outlook, historical trading ...
The following slide deck was published by BeiGene, Ltd. in conjunction with this event. For further details see: BeiGene (BGNE) Presents At 41st Annual Healthcare Conference - Slideshow
News, Short Squeeze, Breakout and More Instantly...
$800 million investment in New Jersey supports global growth and expansion with technologically advanced manufacturing capacity and clinical development capabilities for novel cancer medicines BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today ann...
2024-07-20 02:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BeiGene , Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Aaron Rosenberg as Chief Financial Officer, effective July 22. Mr. Rosenberg will succeed Julia Wang, who is departing to pursue external opportunities and will stay with the C...